Conflict of interest: J.D. Chalmers reports grants or contracts from Grifols, consulting fees from Antabio, AstraZeneca, Boehringer Ingelheim, Chiesi, Glaxosmithkline, Grifols, Insmed, Janssen, Novartis, Pfizer and Zambon, and leadership or fiduciary roles as Chair of European Respiratory Society (ERS) Bronchiectasis Guideline Task Force, Chief Editor of the European Respiratory Journal, and Chair of EMBARC Clinical Research Collaboration. S. Aliberti reports grants or contracts from Insmed, Chiesi and Fisher & Paykel (paid to institution), royalties or licenses with McGraw Hill, consulting fees from Insmed Incorporated, Insmed Italy, Insmed Ireland, Zambon, AstraZeneca UK, AstraZeneca Pharmaceutical, CSL Behring, Grifols, Fondazione Charta, Boehringer Ingelheim, Chiesi Farmaceutici Spa, Zcube, Menarini, MSD Italia, Physioassist SAS and GlaxoSmithKline Spa, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from GlaxoSmithKline Spa, Thermofisher Scientific, Insmed Italy, Insmed Ireland, Zambon and Fondazione Internazionale Menarini, and participation on a data safety monitoring board or advisory board for Insmed Incorporated, Insmed Italy, AstraZeneca UK Limited and MSD Italia. J. Altenburg reports no conflicts of interest. F. Blasi reports grants or contracts from AstraZeneca, Chiesi, GSK and Insmed; consulting fees from GSK, Menarini and OM Pharma; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Chiesi, GSK, Grifols, Insmed, Menarini, Novartis, Ompharma, Pfizer, Sanofi, Vertex, Viatris and Zambon. C. Clarke reports no conflicts of interest. S.H. Chotirmall reports consultancy for Boehringer Ingelheim and Pneumogen, and payment or honoraria from AstraZeneca, Chiesi and Inovio. M.L. Crichton reports no conflicts of interest. R. Dhar reports grants or contracts from Cipla. P. Goeminne reports payment or honoraria for lectures, presentations or educational events from GSK, MSD and Chiesi. C. Haworth reports grants or contracts from the National Institute for Health and Care Research (paid to institution), consulting fees from 30 Technology, CSL Behring, Chiesi, Insmed, Janssen, LifeArc, Meiji, Mylan, Novartis, Pneumagen, Shionogi and Zambon, and payment or honoraria for lectures, presentations, speakers. bureaus, manuscript writing, or educational events from Zambon, Insmed, Chiesi and 30 Technology. M.R. Loebinger reports consulting fees from Armata, 30T, AstraZeneca, Parion, Insmed, Chiesi, Zambon, Electromed, Recode, AN2 and Savara, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Insmed, and a role as the ERS Infection Group chair. N. Lorent reports speaker fees or consultancy for Insmed and GSK. E. Polverino reports grants or contracts from Grifols, consulting fees from Bayer, Zambon, Pfizer, Chiesi, Shire, Shionogi, Insmed, Moderna and Pfizer, payment for expert testimony from Chiesi, leadership or fiduciary roles on the ERS Task Force For Bronchiectasis Guidelines and as co-chair of EMBARC, and receipt of equipment, materials, drugs, medical writing, gifts, or other services from Zambon. F.C. Ringshausen reports grants or contracts from German Center for Lung Research (DZL), German Center for Infection Research (EU and European Federation of Pharmaceutical Industries and Associations; EFPIA), iABC Consortium (including Alaxia, Basilea, Novartis and Polyphor), Mukoviszidose Institute, Novartis, Insmed Germany, Grifols, Bayer and InfectoPharm (paid to institution), consulting fees from Parion, Grifols, Zambon, Insmed and Helmholtz-Zentrum für Infektionsforschung, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from I!DE Werbeagentur, Interkongress, AstraZeneca, Insmed, Grifols, and Universitätsklinikum Frankfurt am Main, payment for expert testimony from Social Court Cologne (paid to institution), support for attending meetings or travel from German Kartagener Syndrome and PCD PAG, and Mukoviszidose, participation on a data safety monitoring board or advisory board for Insmed, Grifols and Shionogi, leadership or fiduciary role in other board, society, committee, or advocacy groups as Coordinator of the ERN-LUNG Bronchiectasis Core Network, Chair of the German Bronchiectasis Registry PROGNOSIS, Member of the Steering Committee of the European Bronchiectasis Registry EMBARC, Co-Speaker of the Medical Advisory Board of the German Kartagener Syndrome and PCD PAG, Speaker of the Respiratory Infections and tuberculosis group of the German Respiratory Society (DGP), Speaker of the Cystic Fibrosis group of DGP, Prinicipal Investigator for DZL, Member of the Protocol Review Committee of the PCD-CTN, and Member of Physician Association of the German Cystic Fibrosis PAG, and fees for clinical trial participation (paid to institution) from AstraZeneca, Boehringer Ingelheim, Celtaxsys, Corbus, Insmed, Novartis, Parion, University of Dundee, Vertex and Zambon. A. Shoemark reports research grants from AstraZeneca. M. Shteinberg reports grants or contracts from GSK and Trudell pharma, consulting fees from AstraZeneca, Boehringer Ingelheim, Dexcel, Kamada, Synchrony Medical, Trumed and Zambon, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Boehringer Ingelheim and Kamada, support for attending meetings or travel from Boehringer Ingelheim, AstraZeneca and Kamada, participation on a data safety monitoring board or advisory board for Bonus Biotherapeutics, Boehringer Ingelheim and AstraZeneca, leadership or fiduciary role in other board, society, committee, or advocacy groups with Israeli Pulmonology Society, Israeli Society for Tuberculosis and Mycobacterial Diseases, EMBARC as unpaid management board member, and ERJ and Chest as unpaid editorial board member, and receipt of equipment, materials, drugs, medical writing, gifts or other services from Trudell Medical International. O. Sibila reports no conflicts of interest. A. Spinou reports no conflicts of interest. T. Welte reports grants or contracts from German Ministry of Research and Education, and consulting fees from AstraZeneca, GSK and Insmed.